Insmed Inc

Common Name

Insmed

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

1,271

Ticker

INSM

Exchange

NASDAQ/NGS

Website

insmed.com

Description

Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for se... Show more

Income Statement Balance Sheet Group Entities

Insmed's Financial Statements Preview

Below are the financial statements of Insmed, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of USD	2024 as of 2024-12-31	2023 as of 2023-12-31
Assets	—	—
Current assets	—	—
Cash and cash equivalents	555.03^a	482.37^a
Marketable securities	878.8^a	298.07^a
Accounts receivable	52.01^a	41.19^a
Inventory	98.58^a	83.25^a
Prepaid expenses and other current assets	37.25^a	24.18^a
Total current assets	1,621.66^a	929.06^a
Fixed assets, net	80.05^a	65.38^a
Finance lease right-of-use assets	18.27^a	20.99^a
Operating lease right-of-use assets	17.26^a	18.02^a
Intangibles, net	58.65^a	63.7^a
Goodwill	136.11^a	136.11^a
Other assets	93.23^a	96.57^a
Total assets	2,025.23^a	1,329.84^a
Liabilities and shareholders' equity	—	—
Current liabilities	—	—
Accounts payable and accrued liabilities	285.21^a	214.99^a
Finance lease liabilities	2.96^a	2.61^a
Operating lease liabilities	9.36^a	8.03^a
Total current liabilities	297.53^a	225.63^a
Debt, long-term	1,103.38^a	1,155.31^a
Royalty financing agreement	161.07^a	155.03^a
Contingent consideration	144.2^a	84.6^a
Finance lease liabilities, long-term	24.06^a	27.03^a
Operating lease liabilities, long-term	9.11^a	11.01^a
Other long-term liabilities	0.5^a	3.15^a
Total liabilities	1,739.85^a	1,661.76^a
Shareholders' equity	—	—
Common stock	1.79^a	1.48^a
Additional paid-in capital	4,645.79^a	3,113.49^a
Accumulated deficit	-4,359.92^a	-3,446.15^a
Accumulated other comprehensive loss	-2.29^a	-0.75^a
Total shareholders' equity (deficit)	285.38^a	-331.92^a
Total liabilities and shareholders' equity (deficit)	2,025.23^a	1,329.84^a

Download Data

Verified Sources Behind Insmed’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Insmed’s data sources below and access millions more through our Disclosure Search.

a. Insmed's 10-K 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Insmed Inc

Insmed's Financial Statements Preview

Verified Sources Behind Insmed’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

TG Therapeutics Inc

ACADIA Pharmaceuticals Inc

Blueprint Medicines Corp

ADMA Biologics Inc

Ultragenyx Pharmaceutical Inc

Halozyme Therapeutics Inc